DPP4 and cancer: CD26/DPP-4 is targeted by inhibitors for the treatment of type-2 diabetes mellitus (76), Crohn’s disease (77) and other inflammatory or autoimmune conditions (72, 73, 76, 78–81) and has been implicated in a wide variety of cancers (82–85).